Age: 65.0
Sex: F
Vaccine: COVID19, FLU3
Symptoms: Brain fog, Head discomfort, Headache, Inflammation, Lymphoid tissue hyperplasia
Clinical narrative: My head feels additional pressure bordering on a headache with brain fog sensation; inflammation on two areas of head that have been problematic with Reactive Lymphoid Hyperplasia (RLH)/Inflammation; inflammation on two areas of head that have been problematic with Reactive Lymphoid Hyperplasia (RLH); My head feels additional pressure bordering on a headache with brain fog sensation/Head pressure; Injection sight muscle pain for 2 days/Vaccination site pain; Redness at injection sight along with active itchiness/Vaccination site erythema; Redness at injection sight along with active itchiness/Vaccination site pruritus; My head feels additional pressure bordering on a headache with brain fog sensation/Headache; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 65-year-old female patient (not pregnant) received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 10Oct2023 at 10:15 as dose 1, single (Lot number: 00069-2362-10) at the age of 65 years, in right arm for covid-19 immunisation; influenza vaccine inact split 3v (FLUZONE HIGH DOSE), on 10Oct2023 as dose 1, single (Lot number: 49281-0123-65), in right arm for influenza immunisation. The patient's relevant medical history included: "Over reaction to gnat/mosquito bites" (unspecified if ongoing). Concomitant medication(s) included: PNEUMOCOCCAL CONJUGATE VACCINE, 20-VALENT intramuscular taken for immunisation, on 04Oct2023 as dose 1, single; KENALOG 40 intra-articular, start date: 10Oct2023. The following information was reported: VACCINATION SITE PAIN (non-serious) with onset 12Oct2023, outcome "recovered" (Oct2023), described as "Injection sight muscle pain for 2 days/Vaccination site pain"; BRAIN FOG (non-serious) with onset 12Oct2023, outcome "not recovered", described as "My head feels additional pressure bordering on a headache with brain fog sensation"; HEAD DISCOMFORT (non-serious) with onset 12Oct2023, outcome "not recovered", described as "My head feels additional pressure bordering on a headache with brain fog sensation/Head pressure"; HEADACHE (non-serious) with onset 12Oct2023, outcome "not recovered", described as "My head feels additional pressure bordering on a headache with brain fog sensation/Headache"; VACCINATION SITE ERYTHEMA (non-serious) with onset 12Oct2023, outcome "not recovered", described as "Redness at injection sight along with active itchiness/Vaccination site erythema"; VACCINATION SITE PRURITUS (non-serious) with onset 12Oct2023, outcome "not recovered", described as "Redness at injection sight along with active itchiness/Vaccination site pruritus"; LYMPHOID TISSUE HYPERPLASIA (non-serious) with onset 12Oct2023, outcome "not recovered", described as "inflammation on two areas of head that have been problematic with Reactive Lymphoid Hyperplasia (RLH)"; INFLAMMATION (non-serious) with onset 12Oct2023, outcome "not recovered", described as "inflammation on two areas of head that have been problematic with Reactive Lymphoid Hyperplasia (RLH)/Inflammation". Therapeutic measures were not taken as a result of brain fog, inflammation, lymphoid tissue hyperplasia, head discomfort, vaccination site pain, vaccination site erythema, vaccination site pruritus, headache.  Additional information: Injection sight muscle pain for 2 days. Day 3- Redness at injection sight along with active itchiness, inflammation on two areas of head that had been problematic with Reactive Lymphoid Hyperplasia (RLH). Patient head feels additional pressure bordering on a headache with brain fog sensation. Covid did not occur prior to vaccination. Covid not tested post vaccination.